A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


March 8, 2014

Gilead’s Combo Therapy Cures Hep C in Just Six Weeks

CROI 2014Just six weeks of Gilead Sciences’ hotly anticipated combination pill of ledipasvir and Sovaldi (sofosbuvir), given with or without GS-9669 or GS-9451, cured 95 to 100 percent of people with genotype 1 of hepatitis C virus (HCV) in a small pilot study, MedPage Today reports. Findings from the SYNERGY study were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

By presenting these findings, Gilead has raised the stakes yet again in the fiercely competitive race to bring highly effective, easily tolerated hep C regimens to market, especially considering the fact that the company studied these drug combinations in a difficult-to-treat population. Current preferred therapeutic options entail 12 to 24 weeks of treatment for most people. Other medication combinations in the pipeline have typically been edging treatment protocols toward 12 or sometimes eight weeks.

The study was divided into three arms of 20 treatment-naive participants with genotype 1 of hep C. In the first arm, participants with all stages of liver fibrosis received 12 weeks of therapy with the coformulated pill of the NS5A inhibitor ledipasvir and the nucleotide analog NS5B polymerase inhibitor Sovaldi. The second and third arms included participants without cirrhosis who received six weeks of treatment with the combination pill plus the non-nucleoside NS5B site 2 polymerase inhibitor GS-9669 in the second arm and the NS3 protease inhibitor GS-9451 in the third arm.

Just one participant, in the arm that included GS-9669, did not achieve a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure). Consequently the respective cure rates in arms one, two and three were 100 percent, 95 percent and 100 percent.

The patient population was traditionally difficult to treat: Most of them had genotype 1a and high hep C viral loads, and about 25 to 30 percent of them had advanced liver disease. About 80 percent were African Americans, who historically have not responded as well to treatment.

To read the MedPage Today story, click here.

To read the conference poster, click here.

Search: Gilead Sciences, GS-9669, GS-9451, ledipasvir, Sovaldi, sofosbuvir, SYNERGY, CROI, Conference on Retroviruses and Opportunistic Infections.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (7 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.